Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amlitelimab in moderate-to-severe atopic dermatitis
NCT06224348Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2024
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of amlitelimab in atopic dermatitis (AD), sponsored by Sanofi. Started Jan 2024; status: completed.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06224348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06224348.